	US 12,454,682 B2
	Engineered glycosyltransferases and steviol glycoside glucosylation methods
Jonathan Vroom, South San Francisco, CA (US); Stephanie Sue Galanie, Knoxville, TN (US); Jack Liang, South San Francisco, CA (US); Joyce Liu, Fremont, CA (US); Nikki Dellas, San Carlos, CA (US); Melissa Ann Mayo, Foster City, CA (US); and David Entwistle, San Carlos, CA (US)
Assigned to TATE & LYLE SOLUTIONS USA LLC, Hoffman Estates, IL (US)
Filed by Tate & Lyle Solutions USA LLC, Hoffmann Estates, IL (US)
Filed on Aug. 2, 2023, as Appl. No. 18/364,419.
Application 18/364,419 is a division of application No. 16/514,578, filed on Jul. 17, 2019, granted, now 11,760,981.
Claims priority of provisional application 62/712,327, filed on Jul. 31, 2018.
Claims priority of provisional application 62/712,199, filed on Jul. 30, 2018.
Prior Publication US 2024/0010999 A1, Jan. 11, 2024
Int. Cl. C12N 9/10 (2006.01); C07H 15/252 (2006.01); C12P 19/56 (2006.01)

CPC C12N 9/1062 (2013.01) [C07H 15/252 (2013.01); C12N 9/1048 (2013.01); C12P 19/56 (2013.01); C12Y 204/01013 (2013.01)]

17 Claims

1. An engineered glycosyltransferase comprising a polypeptide sequence that has at least 90% or more sequence identity to SEQ ID NO: 24, 858, 994, 1080, 1216, 1488, or 1516; wherein said polypeptide sequence comprises one or more mutations relative to the reference sequence of SEQ ID NO: 24, 858, 994, 1080, 1216, 1488, or 1516.